Opinion|Videos|April 11, 2025
Long-Term Efficacy and Safety of IL-17 Inhibitors in Psoriasis
Panelists discuss how long-term data confirm the sustained efficacy and safety of IL-17 inhibitors in psoriasis. Secukinumab (Bissonnette, 2018; Langley, 2022) and ixekizumab (Blauvelt, 2021) show durable PASI responses over 5 years. Brodalumab’s 5-year pharmacovigilance (Lebwohl, 2024) and 120-week data (Puig, 2020) support its long-term use. Bimekizumab’s 4-year data (Blauvelt, 2024; Gordon, 2024) demonstrate continued efficacy, with 5-year results anticipated at AAD 2025.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What do we know about the long-term safety and efficacy of IL-17 inhibitors in psoriasis?
- Secukinumab 5-year data (Bissonnette, 2018;
Langley, 2022 ) - Ixekizumab 5-year data (Blauvelt, 2021)
- Brodalumab 5-year pharmacovigilance (Lebwohl, 2024); 120-week data (Puig, 2020)
- Bimekizumab 4-year data (Blauvelt, 2024; Gordon, 2024); 5-year data expected at AAD 2025
- Secukinumab 5-year data (Bissonnette, 2018;
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Reviewing Type 2 Inflammation Through a Different Lens
3
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
4
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
5
